Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... 2011 As NFL coaches and players face a dramatically ... team,s preparation will be gaining a competitive edge as it ... Today, Polar USA and the Atlanta Falcons announced that the ... Heart Rate Training System" of the Atlanta Falcons. ...
... CINCINNATI, Sept. 7, 2011 HealthWarehouse.com, Inc. (OTC: HEWA) ... that Lalit Dhadphale, president and CEO of HealthWarehouse.com, will ...  The presentation will begin at 10:00 a.m. Eastern Time ... invited to listen to a live web cast of ...
Cached Medicine Technology:Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 3
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... Pharmaceutical Marketing Industry Due to New PhRMA Marketing ... Pharmaceutical marketers are taking on the 2009 ... a unique marketing company whose integrated engagement solutions ... sector. In the past two years the company ...
... Disease Depend on Plasma DonationANNAPOLIS, Md., Jan. 6 Kawasaki ... between the ages of two and five and is ... in the United States according to the American Heart ... globulin (IVIG), a plasma-derived therapy that replaces vital missing ...
... flow leader positioned for expanding role of patient flow ... has been helping its clients, now more than 700 ... The need to increase capacity and improve patient ... of U.S. hospitals have postponed building and expansion plans ...
... Music Organization Will Offer "The Prevention Plan(TM)" Health ... Preventive Medicine(R), the leader in disease prevention, today ... performing right organization that represents more than 375,000 ... Prevention Plan(TM) to its members at a discount. ...
... N.C., Jan. 6 Compass Group North America ... of Harwood Heights,Illinois-based KIMCO Corporation, a provider of ... sector. Through the acquisition, KIMCO,becomes a wholly owned ... a division of Compass Group North America focused ...
... Rising Medical Solutions, Inc. (Rising), a,leading medical ... Company will provide Medical Data Call services for ... data to the National Council on,Compensation Insurance, Inc. ... http://www.newscom.com/cgi-bin/prnh/20080206/AQW030LOGO-b ) , ...
Cached Medicine News:Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 2Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 3Health News:Kawasaki Disease Treated with Plasma-Derived Therapy 2Health News:TeleTracking Technologies to Focus on Growth 2Health News:TeleTracking Technologies to Focus on Growth 3Health News:U.S. Preventive Medicine(R) Strikes a Note with Broadcast Music, Inc. 2Health News:Compass Group North America Acquires KIMCO Corporation 2Health News:Rising Medical Solutions to Provide NCCI Medical Data Call Services 2
... one of our highly featured models. This model has ... target using the mouse to have the patient look ... allow the unit to photograph a particular area on ... after you have taken the picture you can ascertain ...
... laser combines excellent cutting, ablation and ... procedures. It is also extremely effective ... stones of all compositions, making it ... its laser light is transmitted through ...
... Thanks to the progress and perfecting ... techniques have acquired a more strategic role ... technology in this sector has certainly contributed ... various urological pathologies that are becoming more ...
... PhotoLightFACIAL facial skin treatment, vascular ... Incorporates a wide range ... multiple hand pieces and large ... the most flexibility. Compact ...
Medicine Products: